Concerning the risk for worsening HF, SGLT-2 inhibitor treatment was demonstrated to substantially decrease the corresponding risk by 66% (RR = 0.34, 95% CI; 0.19–0.61, I2 = 0%), as shown in Figure 5. This evidence concerns the gene SLC5A2 and hydrops fetalis.